Jounce Therapeutics, Inc. (JNCE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.2100 |
| Open | 1.2000 |
| Bid | 1.1400 x 900 |
| Ask | 1.2700 x 800 |
| Day's Range | 1.1800 - 1.2700 |
| 52 Week Range | 0.5770 - 8.8000 |
| Volume | |
| Avg. Volume | 1,636,145 |
| Market Cap | 62.55M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2400 |
| Earnings Date | Feb 28, 2023 - Mar 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- Zacks
Gilead's (GILD) Application for Trodelvy Gets EMA Validation
Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.
- Zacks
Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy
Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.
- Benzinga
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
Gilead Sciences Inc (NASDAQ: GILD) and Jounce Therapeutics Inc (NASDAQ: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020. GS-1811, an immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment. It is currently in Phase 1 development for solid tumors. Jounce will recei
